semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Osteoarthritis known symptomatic osteoarthritis of the knee patients must have been diagnosed with functional Grades I-III of osteoarthritis according to the modified of the American College of Rheumatology must also have had persistent knee pain associated with osteoarthritis with a baseline score of at least 30 mm on the Patient's Assessment of Arthritis Pain Visual Analog Scale required to suspend all current pain relief medications. Subjects that were currently taking analgesic medications were eligible to participate in the study following a 14 day washout period for NSAIDs, a 7 day washout for narcotics, and a 90 day washout for injected steroids. Subjects currently taking glucosamine, chondroitin sulfate or MSM were only eligible after a 3-month washout period  are currently receiving remission-inducing drugs such as methotrexate or immunosuppressive medications or had received them within the past 3 months had a confounding inflammatory disease or condition (rheumatoid arthritis, gout, pseudo gout, Paget's disease, chronic pain syndrome, etc.) that would interfere with assessment of pain associated with the index knee body weight 250 pounds or greater having a known allergy to eggs or egg products pregnant or breastfeeding women Subjects previously enrolled in a study to evaluate pain relief within the past 6 months or currently involved in any other research study involving an investigational product (drug, device, or biologic) or a new application of an approved product, within 30 days of screening
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  Chronic Kidney Disease Vitamin D Deficiency Coronary Calcification Disorders of Calcium and Bone Metabolism CKD stages 3 or 4 (estimated glomerular filtration rate (eGFR) between 15 and 59) Diagnosis of secondary hyperparathyroidism, which is defined as Elevated intact PTH (iPTH) as per KDIGO guidelines CKD stage 3 (eGFR 30-59) or CKD stage 4 (eGFR 15-29) with iPTH > Upper Limit of Normal for lab (6.8 pmol/L) Presence of Coronary Artery Calcium (CAC > 0) Subject will be able to complete the study, to the best of his/her knowledge  iPTH >1500 pg/ml Current or previous use of bisphosphonates History of parathyroidectomy or anticipated parathyroidectomy History of cinacalcet use History of a solid organ transplant or scheduled date for transplant surgery History of coronary revascularization (coronary artery bypass surgery or percutaneous intervention) History of coronary artifact (e.g. pacemaker, intracardiac defibrillator, artificial valve or biventricular leads) Active atrial fibrillation Weight greater than 300 pounds (due to limitations of equipment) HIV positive
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Anorexia Nervosa Osteoporosis Anorexia Nervosa Women, age 30-70 years Osteoporosis or history of clinical fractures (spine, wrist, hip or ribs)  Diseases known to affect bone metabolism Hyperparathyroidism Medications known to affect bone metabolism in last 12 weeks (or bisphosphonate use in last 1 year) Pregnant and/or breastfeeding Diabetes mellitus History of malignancy involving or affecting the bone, any active malignancy, and/or radiation therapy to the bone Fractures of a bone other than a finger or toe in last 1 year
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease age >18 years eGFR 20-45 by modified MDRD equation protein/creatinine ratio <5 blood pressure <150/95 not taking calcium binder or supplements, vitamin D, or phosphate binders normal serum phosphorus and calcium corrected for albumin and intact PTH <100pg/ml medically stable able to give informed consent and come for all visits  history of significant liver disease or cirrhosis medically unstable unable to tolerate diets
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Vitamin D Deficiency Able to consent and come for a study visit. Male or female males and females ages 18-60  Unable to consent or come to a visit, taking Vitamin D supplements, anticonvulsants, barbiturates, steroids, having granulomatous disease, or liver or kidney disease as these medications and conditions interfere with Vitamin D metabolism
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Rheumatoid Arthritis Adult men and non-pregnant, non-lactating women between 18 and 75 years of age. Sexually active females must be of either non-childbearing potential or willing to comply with the contraceptive requirements Body weight greater >40 kg and <120 kg with a body mass index (BMI) between 19-31 kg/m2 Clinical history of rheumatoid arthritis as defined by ACR Negative urine pregnancy test for women of child bearing age (except those with documented proof of hysterectomy or bilateral oophorectomy) For populations B and C only Currently on a stable dosing regimen of methotrexate 7.5 to 25 mg once weekly, as their only DMARD (no changes in dosing regimen for 4 weeks prior to screening)  History of an acute illness within 2 weeks prior to the study History of drug abuse within 2 years Donation of blood in excess of 500 mL within 56 days prior to the first dose of study medication For group A only Prior treatment with disease modifying anti-rheumatic agents or biologicals
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 21.0-45.0,  Lactation Bone Diseases, Endocrine Group 1: Post-partum (singleton pregnancy) African-American women who are exclusively breastfeeding, defined as 1 or fewer bottles of supplemental formula/day Group 2: Post-partum (singleton pregnancy) African-American women are non-lactating, which is defined as bottle-feeding or having weaned their baby from breastfeeding for at least 4 weeks prior to study Group 3: Controls Healthy non-pregnant African-American women will be race and age-matched to the breast-feeding women in group one. They may not have been lactating or pregnant within the last year  Subjects with cardiac, hypertensive, vascular, renal (serum creatinine of >1.5), pulmonary, endocrine, musculoskeletal, hepatic, hematologic or malignant or rheumatologic disease will be excluded from the study Smokers and those with a history of significant alcohol or drug abuse are excluded Baseline hypertension (systolic BP > 160 mm/Hg) or hypotension (systolic BP < 90 mm/Hg) Subjects taking any chronic medications except stable doses of thyroid hormone, prenatal, vitamin supplements, or oral contraceptives Those who have received any investigational drug in past 90 days will be excluded from the study Women who are currently pregnant will be excluded from the study. Women who became pregnant by In Vitro Fertilization IVF or any hormonal manipulation (i.e. fertility drugs such as clomid ®) are also excluded, as they may have an altered pre-pregnant hormonal state. All women will have a urine pregnancy test performed at each of the two study visits and must not be pregnant in order to continue in the study. Subjects are not allowed to donate blood between study visits
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-75.0,  Myeloproliferative Disorders Kidney Cancer Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Histologically confirmed diagnosis of one of the following Chronic myeloid leukemia (CML) Philadelphia chromosome (Ph) and/or BCR-ABL-positive disease In chronic or accelerated phase Suboptimal response to imatinib mesylate (i.e., no hematologic complete response by 3 months, no major cytogenetic response by 6 months, or no complete cytogenetic response by 1 year) CML in blastic transformation allowed provided patient achieved complete remission (CR) or second chronic phase after treatment with imatinib mesylate or chemotherapy Chronic lymphocytic leukemia meeting one of the following Rai stage III or IV disease Rai stage I or II disease that failed standard therapy (i.e., disease is progressing after ≥ 1 course of standard therapy)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Chronic Kidney Disease Patient with stage 3 -5 chronic kidney disease (that is, eGFR < 60 ml/min per 1.73m2) diagnosed for more than 2 months and not expected to start dialysis within the next 12 months, and Patient with screening echocardiography showing evidence of left ventricular hypertrophy Patient has not received vitamin D therapy in the previous 4 weeks For entry into the Treatment Phase, the subject must have screening iPTH >= 55 pg/ml or 5.8pmol/L (determined by the Nichols second-generation assay or similar assay) serum calcium < 10.2 mg/dL (2.55 mmol/L) serum phosphorus =< 5.2mg/dL (1.68mmol/L) Ca*P product < 54 mg2/dL2 (4.36mmol2/L2) If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is of childbearing potential and practicing birth control measures Patients who provide informed consent for the study  Patient with a history of an allergic reaction or significant sensitivity to vitamin D or vitamin D related compounds Patient with history of renal stones Patient with current malignancy Patients with clinically significant gastrointestinal disease or liver disease Patient with acute renal failure in the recent three months Patient with a history of drug or alcohol abuse within six months prior to the screening phase Patient is known to be human immunodeficiency virus (HIV) positive Patient with evidence of poor compliance with diet and medication Patient currently receiving medications that may affect calcium, phosphorus metabolism such as calcitonin, cinacalcet, bisphophonates or vitamin D compounds (other than study drug), or other drugs that may affect calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy Patients with active granulomatous disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Other Acute Pain Chronic Pain Predominantly axial pain below L5 vertebrae greater than 75%pain relief from 2 seperate lateral branch blocks done on different days chronic axial pain lasting longer than 6 months, 3 day average VAS between 4 and 8 age greater than 18 failed to acheive adequate improvemnet with comprehensive non-operative treatments, includingbut not limited to: activity alteration, non0steriodal anti-iflammatory, physical and/or manual therap, and flurpscopically guided steriod injections in and around the area of pathology all other possible sources oflow back pain have been ruled out, including but not limited to the intervertebral discs, bone fracture  Beck Depression greater than 20% irreversible psychological barriers to recovery spinal pathology that may impede recovery such as spins bifida occulta moderate to severe foraminal or central canal stenosis systemic infection or localized infection at inducer site concomitant cervical or thoracic pain greater than 2/10 on VAS uncontrolled or acute disease chronic severe condition such as rheumatoid arthritis preganancy active radicular pain
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Nicotine Dependence Subjects will be eligible to participate if they: 1. Are at least 18 years of age 2. Have used ST daily for the past 12 months (regular user) 3. Identify ST as their primary tobacco product 4. Are in general good health (determined by medical history and screening physical examination) 5. Has provided written informed consent to participate 6. Are able to participate in all aspects of the study  Individuals will be excluded from study participation if they: 1. Are currently (in previous 30 days) using other behavioral or pharmacologic tobacco cessation programs (i.e., behavioral therapy, nicotine replacement therapy, clonidine, bupropion SR, or doxepin) 2. Have self-reported current, untreated depression or a Beck Depression Inventory (BDI-II) Score of ≥ 20 3. Have, as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale);current non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt (defined as "potentially self-injurious act committed with at least some wish to die, as a result of act.") 4. History of psychosis or bipolar disorder 5. Are currently pregnant or lactating or is of childbearing potential and not willing to use any form of contraception 6. Have another member of their household already participating in this study 7. Are allergic to varenicline 8. Describe having a medical history of Unstable angina Myocardial infarction within the past 3 months Cardiac dysrhythmia other than medication-controlled atrial fibrillation or PSVT Medically-treated or untreated hypertension with BP ≥ 200 systolic OR ≥ 100 diastolic Have other medical or psychiatric conditions that would the participant
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Metabolic Syndrome Patient has a diagnosis of metabolic syndrome according to the modified 2005 AHA/NHLBI Scientific Statement with at least Abdominal obesity defined as: *Males: waist circumference >102cm Females: waist circumference >88cm and two of the following 4 other Triglycerides>150 mg/dL HDL Cholesterol Males: HDL-C<40 mg/dL Females:HDL-C<50 mg/dL Blood pressure Systolic Blood Pressure ≥130 mmHg or Diastolic Blood Pressure ≥85 mmHg  Patient has a BMI > 35. 2. Patient has hypersensitivity or intolerance to ezetimibe or simvastatin or any component of these medications, or to latex. 3. Patient routinely consumes more than 14 alcoholic drinks per week. 4. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent. 5. Patient has a smoking history > 10 pack-years (1 pack-year = at least 20 cigarettes per day for a year) OR patient who has smoked within 3 months prior to Visit 1 (Week -2). 6. Patient has exclusionary laboratory values at Visit 1 (Week -2) as listed in the table below: liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) > 1.5 X ULN with no active liver disease Serum glucose > 7.0 mmol/L Creatine kinase(CK)> 2 X ULN Albumin:creatinine ratio > 34 TSH <0.3 mcIU/mL or > 5.0 mcIU/mL 7. Patient has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate. 8. It is not possible to obtain a FMD measurement of sufficient quality at screening (Visit 1) 9. Patient has congestive heart failure, atherosclerotic vascular disease or acute or chronic coronary heart disease. 13. Patient has had a partial ileal bypass, gastric bypass, gastric banding, celiac disease or other significant intestinal malabsorption. 15. Patient has untreated and uncontrolled hypertension with systolic blood pressure >160 mm Hg or diastolic >100 mm Hg at Visit 1 (Week -2). (Patients with untreated hypertension and with office BP at Visit 1 and Visit 2 averaging 160/100 or less can be enrolled). Patients using blood pressure-lowering medication are excluded. 16. Patient has estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 based on the 4-variable MDRD 17. Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins at Visit 1 (Week -2). 18. Patient has diabetes mellitus defined as a history of diabetes or fasting serum glucose > 126 mg/dL. For the full  please check the protocol
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Postoperative Nausea and Vomiting (ASA) grade I and II, aged (18-70 years) who are scheduled for elective laparoscopic cholecystectomy under general anesthesia at the department of Anesthesia and Intensive Care, University of Jordan, Amman, Jordan between November 2007 and March 2008  All patients who received antiemetics or cortisone within 48 hr before surgery or those who required opioids before and after surgeries Pregnant, breast feeding ladies Any patient with BMI (Body Mass Index) > 34 kg/m² Patient with gastrointestinal, hepatic, renal, mental or psychiatric illnesses or those with history of motion sickness were also excluded from the study protocol
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Secondary Hyperparathyroidism Clinical diagnosis of secondary hyperparathyroidism (iPTH >200 pg/mL to <500 pg/mL) Serum Ca < 11.0 mg/dL, and serum P < 7.0 mg/dL At least one year of regular hemodialysis therapy  Patients with a history of hypersensitivity to any ingredient of maxacalcitol Patients who had received parathyroidectomy